Axogen Inc
$ 38.50
3.02%
17 Apr - close price
- Market Cap 1,998,061,000 USD
- Current Price $ 38.50
- High / Low $ 39.99 / 38.00
- Stock P/E N/A
- Book Value 2.73
- EPS -0.34
- Next Earning Report 2026-04-28
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.14 %
- 52 Week High 39.99
- 52 Week Low 9.22
About
AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.
Analyst Target Price
$41.22
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-10-29 | 2025-08-05 | 2025-04-30 | 2025-02-25 | 2024-11-07 | 2024-08-08 | 2024-05-02 | 2024-03-05 | 2023-11-07 | 2023-08-07 | 2023-05-09 |
| Reported EPS | 0.07 | 0.12 | 0.12 | -0.02 | 0.07 | 0.07 | 0.05 | -0.06 | -0.06 | 0.01 | -0.03 | -0.1 |
| Estimated EPS | 0.0586 | 0.07 | 0.06 | 0.016 | 0.03 | 0.01 | -0.04 | -0.07 | -0.1 | -0.06 | -0.13 | -0.14 |
| Surprise | 0.0114 | 0.05 | 0.06 | -0.036 | 0.04 | 0.06 | 0.09 | 0.01 | 0.04 | 0.07 | 0.1 | 0.04 |
| Surprise Percentage | 19.4539% | 71.4286% | 100% | -225% | 133.3333% | 600% | 225% | 14.2857% | 40% | 116.6667% | 76.9231% | 28.5714% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-28 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.17 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | |
|---|---|---|
| Payment Date | None | None |
| Amount | $1.0 | $0.06 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AXGN
2026-04-17 01:39:37
Axogen Inc. stock reached a new 52-week high of $36.21, reflecting a 123% return over the past year and a 108% surge in the last six months, driven by strong revenue growth and investor confidence in its nerve repair solutions. Despite this peak performance, an InvestingPro analysis suggests the stock is currently overvalued. The company recently surpassed Q4 2025 earnings and revenue expectations, and Citizens reiterated a "Market Outperform" rating with a $42.00 price target.
2026-04-16 19:56:00
Axogen Inc. (AXGN) stock reached a new 52-week high of $36.21, reflecting a 123% return over the past year and a 108% surge in the last six months, driven by 20% revenue growth. Despite this impressive performance and beating recent earnings expectations, InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value. Citizens reiterated a Market Outperform rating with a $42.00 price target.
2026-04-15 00:40:00
Axogen, Inc. announced it will release its first quarter 2026 financial results on Tuesday, April 28, 2026. The company will host an investment-community conference call and webcast at 8:00 a.m. ET to discuss the results, with participation details provided for interested investors. Axogen specializes in surgical solutions for peripheral nerve function restoration and repair, offering a range of products.
2026-04-14 11:16:31
Axogen, Inc. announced that it will release its first-quarter 2026 financial results on Tuesday, April 28, 2026. Following the release, the company will host a conference call and webcast at 8:00 a.m. ET for the investment community. Investors can access the webcast and presentation slides on Axogen's website.
2026-04-14 11:10:19
Axogen, Inc. (Nasdaq: AXGN) announced it will release its first-quarter 2026 financial results on Tuesday, April 28, 2026. Following the release, Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET. Details for accessing the call and webcast are provided for interested investors.
2026-04-13 19:09:31
This article examines unusual options activity for Axogen (NASDAQ: AXGN) to determine if it signals future stock price movements. It highlights a significant options trade involving 500 put options with a strike price of $10 expiring on June 18, 2027, suggesting a bearish outlook. The analysis considers the context of such trades by institutional investors and contrasts it with recent analyst ratings and the company's financial performance.
